Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Personalised medicine in gynaecological cancers

How to test and define HRD positive population in ovarian cancer


09 Oct 2016


Personalised medicine in gynaecological cancers


Iain McNeish


I. McNeish

Author affiliations

  • Wolfson Wohl Cancer Research Centre, University of Glasgow Beatson Institute for Cancer Research, G61 1QH - Glasgow/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings